Here you will find current external funding opportunities available for innovation and research projects.

If you are aware of funding oportunities that are not listed please email the detail to stees.ideas@nhs.net and they will be added to the website.

Biomedical Catalyst round 4: late stage award

This is a competition for a late stage award in the Biomedical Catalyst.

The aim of the Biomedical Catalyst is to support the development of innovative healthcare products, technologies and processes. These can include:

  • disease prevention and proactive management of health and chronic conditions
  • earlier and better detection and diagnosis of disease, leading to better patient outcomes
  • tailored treatments that either change the underlying disease or offer potential cures

The Biomedical Catalyst has 4 types of funding award. These are: feasibility, primer, early stage and late stage. They are designed to help SMEs developing a product or process to provide an innovative solution to a health and care challenge. The scheme supports progression from initial concept through to late stage development.

In Biomedical Catalyst round 4 we have 2 competitions, one focusing on the primer stage award and this one, which is focused on the late stage award. You must submit your project to the competition for the correct award. If you submit for the wrong award your application will be immediately rejected and you will not be able to reapply into this round. You can only submit the same application twice to Innovate UK.

You should have prior credible research on your proposal, including a demonstration of validation in a relevant model system. We welcome applications from any sector or discipline.

Deadline: 7th February 2018 at 1200 hrs

Further information can be found here.

Research for Patient Benefit Programme : Competition 35

Applications are invited for research proposals that are concerned with the day-to-day practice of health service staff, and which have the potential to have an impact on the health or wellbeing of patients and users of the NHS. As a response mode researcher-led programme, RfPB does not specify topics for research, but encourages proposals for projects which address a wide range of health service issues and challenges.  

The programme aims to fund high quality quantitative and qualitative research with a clear trajectory to patient benefit. It particularly encourages applications that have a strong element of interaction with patients and the public, and which have been conceived in association with a relevant group of service users.

Deadline: 21st March 2018 at 1300 hrs

Further information can be found here.

 

NIHR 17/142 - Osteoporosis

The EME Programme invites proposals for research into novel interventions for the improved diagnosis, stratification, prevention or treatment of primary or secondary osteoporosis, to reduce the likelihood of fragility fractures. The EME programme invites applications seeking to evaluate any of a wide range of interventions, although the treatment of fractures is not included in the remit of this call. Applications must concentrate on determining the clinical efficacy of interventions, and the inclusion of embedded hypothesis-driven mechanistic studies within the main clinical evaluation is strongly encouraged.

Deadline: 27th March 2018 at 1300 hrs

Further details can be found here

 

NIHR 17/143 - Inherited myopathies and muscular dystrophies.

A call for research into novel treatments for all aspects of the management of inherited myopathies and muscular dystrophies or their complications. The programme is particularly interested in proposals to evaluate treatments which may benefit more than one condition with an underlying coherent pathophysiology. Proposals that involve international collaboration are welcome. Applications must concentrate on determining the clinical efficacy of interventions, and the inclusion of embedded hypothesis-driven mechanistic studies within the main clinical evaluation is strongly encouraged. It is suggested that applicants may wish to consider the use of existing patient cohorts for recruitment. Muscular Dystrophy UK maintains a list of currently available patient registries in the UK at http://www.musculardystrophyuk.org/progress

Deadline: 27th March 2018 at 1300 hrs

Further details can be found here

 

NIHR 17/144 - Mechanisms of action of behavioural and psychological interventions to improve health

The EME Programme invites proposals for research into the underlying mechanisms of action of interventions that utilise behavioural or psychological techniques to promote or directly improve the health of patients in the NHS. The research should be hypothesis driven and can be prospective, or may be based on the analysis or reanalysis of previously collected data, provided it adds significantly to the scientific understanding of the mechanisms of action of the original intervention. Where the research is retrospective, it may include the collection of new data for additional analysis, provided it is obtained from original study participants. Applicants will need to make a strong case for how a better understanding of the mechanisms of action of the interventions will potentially contribute to their future use or development for the ultimate benefit of individual patients’ or the wider NHS. Projects must have a strong collaborative approach, involving at least two of academia, NHS and industry. The EME Programme is particularly keen to encourage collaboration with small and medium enterprises.

Deadline: 27th March 2018 at 1300hrs

Further details can be found here

 

NIHR 17/145 - Efficacy and Mechanism Evaluation Programme researcher-led

Detailed call specification Applications are sought for research into interventions that are based or used by the NHS and its partners. This document provides the detailed call specification for applications to the EME researcherled workstream. Applicants should note:

  • applications should focus on establishing efficacy of an intervention;
  • proof of concept in humans for the intervention already needs to be established and should be clearly demonstrated in the application;
  • applications may include embedded mechanistic evaluations, however, stand-alone mechanistic studies are excluded from this call;
  • applications may investigate novel or repurposed interventions and tests;
  • the discovery of new biomarkers is excluded from this call;
  • studies involving incremental or minor improvements to existing technologies are excluded from this call.

Applications are expected to set out programmes of work which may contain distinct stages. It is expected that the early stages of the study will, if successful, lead onto a full evaluative clinical study or trial, which is in the remit of the EME Programme. This study must also be included and clearly specified within the application. Clinical trials embedded within the programme of work must be large enough to detect a meaningful effect. Applications to this call may also include initial stages such as:

  • The limited steps needed to progress the development of an intervention to a stage suitable for use in an accredited clinical service;
  • Prospective clinical work or retrospective research utilising existing clinical samples or data to inform the main study;
  • Pilot or feasibility studies.

As a rough guide it is expected that these early stages will be complete within the first 18 months of the project and must not contribute more than 25% to the total cost or duration of the project. Applicants will need to make a strong case for the future importance of the intervention through providing a measurable positive impact on health, innovation or future wealth creation and for the ultimate benefit of individual patients’ or the wider NHS.

Deadline: 27th March 2018 at 1300 hrs

Further details can be found here

 

NIHR 17/146 - Mechanisms of action of health interventions

The EME Programme invites proposals for hypothesis driven research into the underlying mechanisms of action of clinical and public health interventions. Studies must utilise patients or samples from identifiable cohorts from current or completed NIHR-funded or NIHR-managed* studies in any setting. Proposals will be accepted across a wide range of interventions; including behavioural, pharmaceutical, psychological, surgical and public health interventions. The research should be hypothesis driven, relevant to the intervention and outcomes proposed by the original study and add significantly to the scientific understanding of the mechanisms of action of the intervention. The proposed research may involve the analysis or reanalysis of previously stored specimens or data, or the collection of new specimens or new data for additional analysis, provided it is obtained from study participants. Discovery of new biomarkers is not within the remit of the EME Programme. Applicants will need to make a strong case for how a better understanding of the mechanisms of action will potentially contribute to the future use or development of the technology, future wealth creation and for the ultimate benefit of individual patients’ or the wider NHS.

Deadline: 27th March 2018 at 1300hrs

Further details can be found here

 

 

NIHR 17/147 - Health Technology Assessment Programme researcher-led primary research

Proposals should normally evaluate the clinical and cost effectiveness of a health technology. For diagnostic technologies, researchers may suggest equivalent evaluations. We are interested in receiving proposals addressing any health problem in areas not otherwise well covered in our portfolio.

Please note that proposals should be within the scope of the HTA Programme. Proposals to investigate the organisation of health services, or services entirely outside the NHS will not be eligible.

Deadline: 28th March 2018 at 1300 hrs

Futher information can be found here

 

NIHR 17/148 - Health Technology Assessment Programme researcher-led evidence synthesis

The NIHR HTA Programme funds research to assess the effectiveness of technologies within the NHS. In this researcher-led workstream, grants are available for primary research and evidence synthesis on topics proposed by the researchers.

Proposals should normally evaluate the clinical and cost effectiveness of a health technology. For diagnostic technologies, researchers may suggest equivalent evaluations. We are interested in receiving proposals addressing any health problem in areas not otherwise well covered in our portfolio. Please note that proposals should be within the scope of the HTA Programme. Proposals to investigate the organisation of health services, or services entirely outside the NHS will not be eligible.

Deadline: 28th March 2018 at 1300hrs

Further details can be found here

18/02 - Health Services & Delivery Research Programme (Complex health and Care Needs in Older People)

The researcher-led workstream welcomes stage 1 proposals on topics or research questions identified by researchers within the programme’s remit. The aim is to fund research that will lead to improvements in health services that will be of greatest benefit to the NHS and to patients. We are interested in a range of types of research including primary research and evidence synthesis. We are particularly keen to see large scale studies of national importance. This means primary research projects which:

• Address an issue of major strategic importance to the NHS, with the cost in line with the significance of the problem to be investigated

• Are likely to lead to changes in practice that will have a significant impact on a large number of patients across the UK

• Aim to fill a clear 'evidence gap', and are likely to generate new knowledge of direct relevance to the NHS

• Have the potential for findings to be applied to other conditions or situations outside the immediate area of research

• Bring together a team with strong expertise and track record across the full range of relevant disciplines

• Will be carried out across more than one research site.

Deadline: 26th April 2018 at 1300hrs

Further information can be found here

NESTA - Impact Investment Fund

The Fund invests between £150k and £1m in social ventures developing innovations that tackle the major challenges faced by older people, children and communities in the UK. An experienced team of sector experts, venture capitalists, impact investors and evaluators backed by Nesta, provide expertise and guidance, helping companies to grow their reach, demonstrate their impact and become financially sustainable

Deadline:Ongoing

Further information can be found here.

Innovate UK - Tackling Drug Resistance: UK-China

The Department of Health – working in collaboration with Innovate UK – is to invest up to £10 million of Official Development Assistance (ODA) funding in bilateral R&D projects between the UK and China which address the growing threat of antimicrobial resistance.

Deadline: Not yet announced (competition will open in early 2018)

Further details can be found here.

Wellcome Trust - Innovator Award

Up to £500,000 available for up to 24 months to support researchers who are transforming great ideas into healthcare innovations that could have a significant impact on human health. The current focus areas are mental health, neurological disorders and neglected tropical diseases (although applications from other areas may be considered).

Deadline: Ongoing

Further information can be found here.

Horizon 2020 - Health, Demographic Change and Wellbeing

Horizon 2020 is the EU’s largest research and innovation funding programme, with over 1 billion Euros earmarked for calls in 2018/2019. Funding opportunities will be promoted  for health, demographic change and wellbeing. An information day will be held on 8th December in Brussels to learn more about these funding opportunities.

Deadline: Not yet announced

Further details can be found here.